-+ 0.00%
-+ 0.00%
-+ 0.00%

Zhitong Finance App News, Shiyao Group (01093.HK) announced that the Bartolizumab injection (subcutaneous injection) (product name: Enlida®) (product) authorized by the company's subsidiary, Shiyao Group Enbipu Pharmaceutical Co., Ltd., has obtained a drug registration certificate issued by the China National Drug Administration (NDRA) to treat adult systemic myasthenia gravis (GmG) patients with positive anti-acetylcholine receptor (AChR) antibodies.

Zhitongcaijing·10/23/2026 00:25:05
Listen to the news
Zhitong Finance App News, Shiyao Group (01093.HK) announced that the Bartolizumab injection (subcutaneous injection) (product name: Enlida®) (product) authorized by the company's subsidiary, Shiyao Group Enbipu Pharmaceutical Co., Ltd., has obtained a drug registration certificate issued by the China National Drug Administration (NDRA) to treat adult systemic myasthenia gravis (GmG) patients with positive anti-acetylcholine receptor (AChR) antibodies.